ClinicalTrials.gg

Fibromyalgia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,244 studies for Fibromyalgia across more than 10 countries. 256 are recruiting or about to start. 1,037 of them are mainly about Fibromyalgia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,516 studies for Fibromyalgia. How that becomes 1,242 here

This page counts the studies the registry files under Fibromyalgia, and those it files under no condition that list Fibromyalgiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,516Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2List Fibromyalgia as a condition, but the registry did not file them under itMost often written as “Juvenile Fibromyalgia” (1) and “Chronic Fatigue-Fibromyalgia Syndrome” (1). The registry filed them under other conditions only, most often Musculoskeletal Pain (1) and Fatigue Syndrome, Chronic (1).
  3. −272Match it another way24 name it in the title, 1 in a keyword, and 247 by a synonym or other text the search reads.
  4. 1,242The count on this page5 of them list Fibromyalgia in their own words; the registry filed them under no condition.

Status

Completed
761
Recruiting
161
Status unknown
128
Not yet recruiting
67
Terminated
38
Active, not recruiting
34

Phase

Phase 2
109
Phase 3
96
Phase 4
50
Phase 1
31
Early Phase 1
10

Where

United States
369
Turkey
195
Spain
151
Brazil
60
France
49
Canada
42

Who develops what

Add Fibromyalgia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months. Compare Axsome Therapeutics and Ono Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
PregabalinEarlier only
Evidence
  • NCT02187159 · Daiichi Sankyo · Phase 3 · comparator · “Pregabalin” · registered Jul 2014
  • NCT02187471 · Daiichi Sankyo · Phase 3 · comparator · “Pregabalin” · registered Jul 2014
  • NCT02146430 · Daiichi Sankyo · Phase 3 · comparator · “Pregabalin” · registered May 2014
  • NCT00696787 · Pfizer · Phase 2 · comparator · “Lyrica® (Pregabalin)” · registered Jun 2008
Viatris Inc.63% of its industry studiesUS: off-patent, 23 generics marketedEU: off-patent, 4 generics authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Fibromyalgia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 4 open · Psychedelics 3 open · SNRIs 2 open · Corticosteroids 1 open · SSRIs 6

Coming up

98studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger. 15 (9%) take children under 18. 40 (25%) are for women only and 0 (0%) for men only; 35 (22%) take healthy volunteers.

Recruiting studies that take each age, of 161
AgeWomenMen
1012 (7%)11 (7%)
18136 (84%)105 (65%)
30153 (95%)114 (71%)
40154 (96%)115 (71%)
50151 (94%)115 (71%)
65133 (83%)103 (64%)
7575 (47%)66 (41%)
8554 (34%)49 (30%)

Across all 1,244 studies, recruiting or not: 61% stop at 75 or younger and 45% at 65; 6% take children; 30% are for women only and <1% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Fibromyalgia studies take

Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 220 mo13–35 · 24 studies——
Phase 320 mo15–26 · 17 studies——
Interventional, no phase15 mo6–30 · 451 studies—16 mo6–31 · 438 studies
Observational27 mo8–91 · 88 studies—25 mo8–109 · 81 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,244. Browse all 1,244 → or search them.